Gastrointestinal Cancer

Did you catch all of this week's top oncology news? Test your knowledge with OncLive's Weekly News Quiz.

A preclinical study reveals that impaired functioning of 2 enzymes contributes to the development and progression of precancerous lesions in the pancreas.

Peter Enzinger, MD, discusses diagnostic pathways, the role of surgery, and ongoing trials of interest in esophageal cancer in this clinician-focused FAQ.

The investigational pan-RAS inhibitor generated robust responses across 2 phase 1 dose-escalation studies that numerically exceeded historical benchmarks.

Tovecimig plus paclitaxel improved PFS vs paclitaxel alone in COMPANION-002, though crossover effects complicated OS outcomes.

The agency has set a target action date of August 25, 2026, for the sBLA, which is supported by data from the phase 3 HERIZON-GEA-01 trial.

The top 5 OncLive TV videos of the week cover insights in head and neck cancer, esophageal cancer, renal cell carcinoma, and breast cancer.

The FDA grants priority review to enfortumab vedotin-ejfv sBLAs in MIBC, the review period for subcutaneous isatuximab BLA in myeloma has been extended, and more.

Peter C. Enzinger, MD, discusses the significance of Claudin 18.2 and HER2 as actionable biomarkers in gastroesophageal cancer.

The FDA granted priority review to an I-DXd BLA for extensive-stage small cell lung cancer, a sBLA for zenocutuzumab in NRG1+ cholangiocarcinoma has been submitted to the FDA, and more.

Did you catch all of this week's top oncology news? Test your knowledge with OncLive's Weekly News Quiz.

An sBLA seeking the approval of zenocutuzumab has been submitted to the FDA, and the agent was added to the NCCN guidelines for NRG1-positive cholangiocarcinoma.

The top 5 OncLive TV videos of the week cover insights in mantle cell lymphoma, chronic lymphocytic leukemia, salivary gland cancer, cholangiocarcinoma, and prostate cancer.

Lipika Goyal, MD, contextualizes the safety profile of lirafugratinib with that of other FGFR inhibitors in FGFR2-altered cholangiocarcinoma.

Lipika Goyal, MD, discusses results from the phase 1/2 ReFocus trial shared during the 2026 Gastrointestinal Cancers Symposium.

Lipika Goyal, MD, discusses the highly selective, irreversible mechanism of lirafugratinib and its potential to overcome resistance in FGFR2-altered CCA.

In case you missed any, check out our recap of the episodes of OncLive On Air that aired in March 2026.

The FDA grants full approval to brexu-cel in mantle cell lymphoma, grants priority review to a lirafugratinib NDA in FGFR2+ pretreated cholangiocarcinoma, and more.

Did you catch all of this week's top oncology news? Test your knowledge with OncLive's Weekly News Quiz.

A trend toward improved OS was also observed when the dual immunotherapy regimen was added to TACE and lenvatinib in this patient population.

Shubham Pant, MD, MBBS, discusses recent treatment advancements across gastrointestinal malignancies.

Here is your cheat sheet to all therapeutic options that were cleared by the FDA in March 2026 spanning tumor types.

An NDA for lirafugratinib in pretreated, FGFR2-altered cholangiocarcinoma was accepted for FDA review and assigned a PDUFA date of September 27, 2026.

We recap the top regulatory decisions of March in GI malignancies.

Drs Marshall and Lieu discuss the clinical relevance of KRAS G12C and pan-RAS inhibitors in the management of pancreatic and colorectal cancers.